CIK 0001658551 · Non-accelerated filer<br>Smaller reporting company
Amylyx Pharmaceuticals, Inc.
Sign in to watch- Ticker
- AMLX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 464600503
- Phone
- 617-682-0917
- Business address
- 55 CAMBRIDGE PARKWAY, SUITE 6W, CAMBRIDGE, MA, 02142
- 4 Open-market sale Chief Commercial Officer sold 2,403 shares at an average $36.30 ($87,225)
- 4 Open-market sale Co-Chief Executive Officer sold 5,968 shares at an average $36.30 ($216,629)
- 4 Option exercise Chief Financial Officer acquired 5,000 shares (option exercise)
- 8-K Event Material agreement
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- 8-K Event Executive or director change
- 424B4 Offering Prospectus
- EFFECT Other Notice of Effectiveness
- S-1MEF Other S-1MEF
- CORRESP Other Correspondence Between Filers and SEC Staff
- CORRESP Other Correspondence Between Filers and SEC Staff
- S-1 Offering Registration Statement
- SC 13D/A Stake Beneficial Ownership Report
- 8-K Event Other events
- SC 13G Stake Amended Statement of Ownership
- SC 13G/A Stake Amended Statement of Ownership
- 4 Open-market sale 10% owner sold 1,400,000 shares at an average $29.80 ($41,719,639)
- UPLOAD Other SEC-generated Letter
- DRS Other Draft Registration Statement
Page 18 of 23 · 446 filings